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patients with chronic kidney disease (CKD) than in the
general population, and the risk of CVD increases with
reductions in renal function. However, the incidence of CVD
in Japanese patients with CKD has not been sufﬁciently
investigated. To measure this we conducted the Chronic
Kidney Disease Japan Cohort (CKD-JAC) Study over four
years in 2,966 Japanese patients with CKD to examine the
incidence of CVD and all-cause death. These patients had
an estimated glomerular ﬁltration rate (eGFR) of 10–59
ml/min/1.73 m2, were under nephrologist care, and pooled
from 17 medical institutions in Japan. At the median
follow-up of 3.9 years, 69 patients had died, 217 had
cardiovascular events, and 514 started maintenance
dialysis therapy. The incidences of cardiovascular events
were 11.9, 19.1, 25.0, and 39.4 per 1,000 person-years at
eGFRs of 45–59, 30–44, 15–29, and under 15 ml/min/
1.73 m2, respectively. The adjusted Cox proportional
hazards models showed that the risk of cardiovascular
events increased as the eGFR decreased, with a signiﬁcant
difference only between CKD stage G5 (eGFR: under
15 ml/min/1.73 m2) and CKD stage G3a (eGFR: 45–59
ml/min/1.73 m2) (hazard ratio 3.16, 95% conﬁdence interval
1.28 to 7.76). Thus, the risk of CVD and all-cause death
was related to the decrease in eGFR, but not necessarily
elevated in proportion to progression of the CKD stage
in Japanese patients with predialysis CKD under a
nephrologist’s care.
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Kidney International (2017) 91, 227–234C hronic kidney disease (CKD), an independent riskfactor for end-stage renal disease (ESRD), cardiovascu-lar disease (CVD), and all-cause mortality in the gen-
eral population in Western countries1–4 has become a
worldwide public health problem.
Japan is one of the countries with the highest incidence of
ESRD, and the number of Japanese patients with ESRD has
increased over the past 4 decades. In 2013, the number of
ESRD patients on chronic dialysis exceeded 310,000.5 The
number of CKD patients is estimated to be 13.3 million
(corresponding to 13% of the adult population) in Japan.6
However, patients with predialysis CKD have not been
examined sufﬁciently because few cohort studies have been
conducted. Recent population-based studies in Japan also
have conﬁrmed CKD as a signiﬁcant risk for CVD and all-
cause mortality, suggesting that CKD represents a major
public health problem that is independent of ethnicity.7–9
Nevertheless, few prospective observational studies have
been conducted to investigate cardiovascular events in the
CKD patient population. The Chronic Renal Insufﬁciency
Cohort (CRIC) Study10 was conducted in the United States to
examine risk factors for the progression of CKD with respect
to the development of CVD in CKD patients, as well as to
develop models for CVD development that could identify the
high-risk subgroups. Hence, we intended to address the same
challenges in a 4-year, multicenter, prospective cohort study,
the Chronic Kidney Disease-Japan Cohort (CKD-JAC) Study.
The design and methods of the CKD-JAC Study have been
published previously.11 The incidences of coronary artery
disease and stroke events among cardiovascular events differ
between Western and Asian populations, and the risk of
coronary artery disease is much lower in the Japanese general
population.12 The aim of the present study was to investigate
the incidence of the primary end points, cardiovascular
events, and all-cause death in Japanese patients with pre-
dialysis CKD deﬁned as an estimated glomerular ﬁltration
rate (eGFR) of 10 to 59 ml/min/1.73 m2.RESULTS
Patient disposition is shown in Figure 1. A total of 421
patients were lost to follow-up evaluation because they227
Figure 1 | Patient disposition. CV, cardiovascular.
c l i n i ca l i nves t iga t i on K Tanaka et al.: CVD risk in Japanese patients with CKDtransferred to other medical institutions or stopped visiting
the hospital as a result of socioeconomic reasons, and the
follow-up evaluation of 514 patients was terminated because
maintenance dialysis therapy was initiated. Baseline clinical
and laboratory characteristics of Japanese patients with pre-
dialysis CKD by CKD stage have been published previously.13
Overall, 217 cardiovascular events and 69 all-cause deaths
occurred, with only 17 cardiovascular deaths. The differences
in the incidences of cardiovascular events among the 17
centers in the cohort are shown in Supplementary Table S1.
The incidences of cardiovascular events and all-cause death
were 22.8 and 7.2 per 1000 person-years, respectively, and
they showed increases with decreases in eGFR (Figure 2). The
incidences of cardiovascular events were increased signiﬁ-
cantly in patients with diabetes mellitus (DM) compared with
patients without it (Table 1); however, the incidences of
myocardial infarctions and cardiovascular death were mark-
edly low both in patients with DM and in those without
(Table 2). Signiﬁcant differences (P < 0.001) were found in
the incidence of cardiovascular events and primary end points
(cardiovascular events plus all-cause death) with CKD stages
at baseline in Japanese patients with predialysis CKD
(Figure 3 and Supplementary Figure S1). The Cox propor-
tional hazards models unadjusted for confounding factors
showed signiﬁcant associations between CKD stage at baseline
and the primary end points (Table 2); however, these
signiﬁcant associations were weakened after multivariate
adjustments for confounding factors (model 1, adjustment for
age and sex; model 2, adjustment for covariates in model 1228plus classic cardiovascular risk factors such as body mass
index, DM, current smoking, systolic blood pressure, and
history of cardiovascular disease; model 3, adjustment for
covariates in model 2 plus CKD-related cardiovascular risk
factors such as hemoglobin, serum albumin, urine albumin,
and high-sensitivity C-related protein). The risk of the
primary end points was signiﬁcantly different only between
CKD stage G5 (eGFR, <15 ml/min/1.73 m2) and CKD stage
G3a (eGFR, 45–59 ml/min/1.73 m2) (hazard ratio, 3.155;
95% conﬁdence interval, 1.284–7.756; P ¼ 0.012) (Table 2,
model 3).
Associations between CKD stage at baseline, cardiovascu-
lar events, and the primary end points in patients with or
without DM also were investigated. The incidence of both
cardiovascular events and the primary end points increased
signiﬁcantly (P ¼ 0.002) with progression of CKD stage at
baseline in DM (Figure 4a and Supplementary Figure S2).
Signiﬁcant differences (P ¼ 0.038) were found in the
incidences of the primary end point along with CKD stage at
baseline in patients without DM (Supplementary Figure S3),
but not in the incidences of cardiovascular events (Figure 4b).
The Cox proportional hazards models adjusted for con-
founding factors showed signiﬁcant associations between
CKD stage at baseline and the primary end points only in
patients with DM (Table 3). Table 4 shows the comparison of
the incidences of cardiovascular disease and death among the
present study, CKD cohorts of the United States, and epide-
miologic cohorts of Japan and the United States. The
incidences of both cardiovascular disease and all-cause deathKidney International (2017) 91, 227–234
Figure 2 | Incidences of cardiovascular events and all-cause death by chronic kidney disease (CKD) stage at baseline in Japanese
patients with predialysis CKD. The incidences of cardiovascular events also are shown separately by myocardial infarction, cerebrovascular
disease, congestive heart failure, others, and cardiovascular death (others included angina pectoris, sudden death, arrhythmias, chronic
arteriosclerosis obliterans, and aortic dissection). eGFR, estimated glomerular ﬁltration rate.
K Tanaka et al.: CVD risk in Japanese patients with CKD c l i n i ca l i nves t iga t ionwere lower in the present study than in CRIC and the African
American Study of Kidney Disease and Hypertension, espe-
cially for myocardial infarction.14–16
DISCUSSION
The CKD-JAC Study, a large-scale, prospective cohort study,
showed for the ﬁrst time the incidences of cardiovascular
events and all-cause death in Japanese patients with pre-
dialysis CKD, deﬁned as an eGFR of 10 to 59 ml/min/1.73 m2,
under nephrology care. The incidences of cardiovascular
events and all-cause death increased as the eGFR decreased,
but they were very low at all CKD stages compared with those
published in prior studies of CKD cohorts in Western
countries (Table 4).14,15 Prior epidemiologic studies haveTable 1 | Cardiovascular events and all-cause death in Japanese p
DM
Outcome
Rate per 1000 person-years
Total cohort
(n [ 2966)
DM
(n [ 1117)
N
(n
Cardiovascular events 22.8 41.3
Myocardial infarction 1.6 3.0
Angina pectoris 4.6 7.7
Sudden death 0.7 0.3
Congestive heart failure 8.6 17.5
Arrhythmias 0.1 0.3
Cerebrovascular disease 5.3 9.2
Chronic arteriosclerosis obliterans 1.4 3.3
Aortic dissection 0.4 0.0
Cardiovascular death 1.8 2.4
All-cause death 7.2 8.9
Total follow-up time (person-years)
DM, diabetes mellitus.
aP value for DM vs. non-DM is calculated to assume the incidence rate difference is dis
Kidney International (2017) 91, 227–234shown that patients with decreased kidney function
(i.e., patients with CKD) are at higher risk for cardiovascular
events and death than the general population, and that the
risk increases proportionately with decreases in GFR.1 Inter-
estingly, the risk of developing a cardiovascular event or death
was not necessarily in proportion to progression of the CKD
stage in the present study.
As shown in Table 4, the incidences of cardiovascular events
were reported to be much lower in Japanese cohort studies,
such as the Japan Arteriosclerosis Longitudinal Study and the
Hisayama study, than in Western counterparts.12,17–20 The in-
cidences of cardiovascular events were lower in the present
study than in the CKD cohort in the United States and were as
low as in the epidemiologic studies in Japan.atients on predialysis chronic kidney disease with and without
P valuea
Number of events
on-DM
[ 1849)
Total cohort
(n [ 2966)
DM
(n [ 1117)
Non-DM
(n [ 1849)
12.6 0.001 217 139 78
0.8 0.139 15 10 5
2.9 0.244 44 26 18
1.0 0.019 7 1 6
3.7 0.002 82 59 23
0.0 0.011 1 1 0
3.2 0.176 51 31 20
0.3 <0.001 13 11 2
0.6 0.46 4 0 4
1.5 <0.001 17 8 9
6.3 0.293 69 30 39
9537.7 3366.1 6171.6
tributed normally.
229
Table 2 | Associations between chronic kidney disease stage at baseline and the primary end points according to 3 Cox
proportional hazards models adjusted for confounding factors in Japanese patients with predialysis chronic kidney disease
eGFR and CKD stages
Unadjusted Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
eGFR (per 10 ml/min/
1.73 m2 decrease)
1.322 (1.172–1.491) <0.001 1.280 (1.130–1.451) <0.001 1.313 (1.136–1.517) <0.001 1.337 (1.104–1.618) 0.003
G3a (eGFR, $45 ml/min/
1.73 m2)
Reference Reference Reference Reference
G3b (eGFR, $30 to 44
ml/min/1.73 m2)
1.614 (0.893–2.915) 0.113 1.270 (0.702–2.297) 0.43 1.393 (0.706–2.751) 0.339 1.255 (0.548–2.875) 0.592
G4 (eGFR, $15 to 29
ml/min/1.73 m2)
2.079 (1.163–3.717) 0.014 1.602 (0.894–2.870) 0.114 1.669 (0.857–3.251) 0.132 1.507 (0.656–3.465) 0.334
G5 (eGFR, <15 ml/
min/1.73 m2)
3.213 (1.715–6.020) <0.001 2.528 (1.343–4.757) 0.004 3.107 (1.521–6.347) 0.002 3.155 (1.284–7.756) 0.012
Model 1 was adjusted for age and sex; model 2 was adjusted for covariates in model 1 plus body mass index, diabetes mellitus, current smoking, systolic blood pressure, and
history of cardiovascular disease; and model 3 was adjusted for covariates in model 2 plus hemoglobin, serum albumin, urine albumin, and high-sensitivity CRP.
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio.
c l i n i ca l i nves t iga t i on K Tanaka et al.: CVD risk in Japanese patients with CKDThe incidences of death caused by cardiovascular events were
reportedly much higher than of the initiation of renal replace-
ment therapy inWestern countries,2 but the number of patients
who started maintenance dialysis therapy in the study period
was greater than the number of deaths (514 and 69, respectively)
in the present study. The present results may indicate that the
risk of ESRD is higher than that of death or CVD in Japanese
patients with CKD. This might be one of the characteristics of
Japanese patients with CKD and one of the reasons that the
number of patients on chronic dialysis is increasingmarkedly in
Japan. A close investigation of incidences or the risks of death
and CVD after initiation of maintenance dialysis therapy also
may be necessary in this cohort.
One of the objectives of the CKD-JAC Study was to
establish a Japanese cohort for comparison with the CRICFigure 3 | Kaplan–Meier curves for the incidence of cardiovascular e
Japanese patients with predialysis CKD. Log-rank P < 0.001 (no cons
noncardiovascular death as a competing event).
230Study in the United States (a prospective cohort study
investigating risk factors for the progression of CKD and the
development of cardiovascular events in patients with pre-
dialysis CKD). The CRIC Study consisted of 3939 CKD
patients with an eGFR of 20 to 70 ml/min/1.73 m2, 42%,
42%, and 13% of whom were white, black, and Hispanic,
respectively. The incidences of cardiovascular events in the
entire cohort were 13, 6, 26, and 31 per 1000 person-years for
myocardial infarction, cerebrovascular disease, congestive
heart failure, and death, respectively; the composite incidence
of the ﬁrst 3 conditions and cardiovascular events was 38 per
1000 person-years.14 The incidences of myocardial infarction,
cerebrovascular disease, congestive heart failure, and cardio-
vascular death were 1.6, 5.3, 8.6, and 1.8 per 1000 person-
years, respectively, in the CKD-JAC. Again, the incidencesvents by chronic kidney disease (CKD) stage at baseline in
ideration of competing events), and P < 0.001 (treating
Kidney International (2017) 91, 227–234
Figure 4 | Kaplan–Meier curves for the incidence of cardiovascular events by chronic kidney disease (CKD) stage at baseline in
Japanese patients (a) with predialysis CKD and diabetes mellitus (DM) and (b) with predialysis CKD who did not have DM. (a) Log-rank
P ¼ 0.002 (no consideration of competing events), and P ¼ 0.003 (treating noncardiovascular death as a competing event). (b) Log-rank P ¼
0.270 (no consideration of competing events), and P ¼ 0.299 (treating noncardiovascular death as a competing event).
K Tanaka et al.: CVD risk in Japanese patients with CKD c l i n i ca l i nves t iga t ionof cardiovascular events and all-cause death were much lower
in the CKD-JAC Study than in the CRIC Study. As mentioned
earlier, prior epidemiologic studies in the general population
have shown that the risk of cardiovascular events, especially
coronary artery disease, is lower in Japanese than in Western
populations. Apart from racial differences, patient charac-
teristics differed considerably between the CKD-JAC Study
and the CRIC Study, which included age, prevalence of DM,Kidney International (2017) 91, 227–234body mass index (BMI), history of CVD, blood glucose
control level in patients with DM, and the proportion of
patients who received angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers.13 In particular,
the proportion of patients with DM in the CRIC Study was
48.4%, which was higher than the 37.6% in the CKD-JAC
Study. Furthermore, the blood glucose level as assessed by
hemoglobin A1c in patients with DM was managed better in231
Table 3 | Associations between chronic kidney disease stage at baseline and the primary end points according to a Cox
proportional hazards model with or without adjustment for confounding factors in Japanese patients with predialysis chronic
kidney disease with and without diabetes mellitus
eGFR and CKD stages
Unadjusted Adjusted for age and sex
HR (95% CI) P value HR (95% CI) P value
DM
eGFR (per 10 ml/min/1.73 m2 decrease) 1.308 (1.122–1.526) 0.001 1.326 (1.133–1.552) 0.001
G3a (eGFR, $45 ml/min/1.73 m2) Reference Reference
G3b (eGFR, 30–44 ml/min/1.73 m2) 1.401 (0.658–2.979) 0.382 1.254 (0.589–2.673) 0.557
G4 (eGFR, 15–29 ml/min/1.73 m2) 1.797 (0.858–3.764) 0.121 1.627 (0.775–3.416) 0.199
G5 (eGFR, <15 ml/min/1.73 m2) 3.170 (1.443–6.961) 0.004 3.145 (1.428–6.926) 0.004
Non-DM
eGFR (per 10 ml/min/1.73 m2 decrease) 1.293 (1.062–1.574) 0.010 1.201 (0.978–1.476) 0.081
G3a (eGFR, $45 ml/min/1.73 m2) Reference Reference
G3b (eGFR, 30–44 ml/min/1.73 m2) 1.763 (0.681–4.566) 0.243 1.287 (0.496–3.342) 0.604
G4 (eGFR, 15–29 ml/min/1.73 m2) 2.189 (0.856–5.598) 0.102 1.528 (0.595–3.921) 0.378
G5 (eGFR, <15 ml/min/1.73 m2) 2.571 (0.891–7.419) 0.081 1.677 (0.576–4.883) 0.343
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio.
c l i n i ca l i nves t iga t i on K Tanaka et al.: CVD risk in Japanese patients with CKDthe CKD-JAC Study (mean hemoglobin A1c level, 6.8%) than
in the CRIC Study (mean hemoglobin A1c level, 7.7%). A
large difference also was found in BMI between the CRIC
Study (mean BMI, 32.1 kg/m2) and the CKD-JAC Study
(mean BMI, 23.5 kg/m2). Patients with a BMI of 30 kg/m2 or
greater accounted for 55% of patients in the CRIC Study, in
contrast to only 5% in the CKD-JAC Study. The rate of
angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker administration also differed: 68% in the
CRIC Study and 90% in the CKD-JAC Study. These differ-
ences may reﬂect differences in cardiovascular risk between
the 2 cohorts. All patients in the CKD-JAC Study were under
nephrology care and were managed appropriately for blood
pressure, anemia, blood glucose level, and other variables.
Furthermore, these patients also strictly were instructed about
lifestyle and diet by nurses, with guidance by nutritionists.
Because recent population-based studies in Japan have
conﬁrmed CKD as a signiﬁcant risk for cardiovascular
events,7–9 CKD represents a major public health problem that
is independent of ethnicity. The fact that the incidences ofTable 4 | Comparison of the incidences of cardiovascular disease
cohorts in the United States and Japan
Study Subjects Country
Cardio
dis
CKD-JAC CKD patients (eGFR 10–59
ml/min/1.73 m2)
Japan
CRIC14 CKD patients (eGFR 20–70
ml/min/1.73 m2)
United States
AASK15,16 CKD patients (GFR 20–65
ml/min/1.73 m2)
United States
Framingham (M/F)19,20 General population United States
MONICA-US (M/F)17 General population United States
MONICA-JP (M/F)17 General population Japan
Hisayama (M/F)18 General population Japan
JALS (M/F)12 General population Japan
AASK, African American Study of Kidney Disease and Hypertension; CKD-JAC, Chronic Ki
Japan Arteriosclerosis Longitudinal Study; M, male; MONICA, Monitoring of Trends and
232cardiovascular events were low, as in the general population,
might suggest that stricter control may have reduced the risk
of cardiovascular events in patients with CKD, although
selection bias (selecting patients who were more conscious of
their treatment) at the time of patient enrollment cannot be
ruled out.
DM, an important risk factor for CVD, is a major
underlying disease for ESRD in Japan. An observational
cohort study of CKD patients living in Miyagi Prefecture,
Japan, showed the following: the risk of cardiovascular events
increased together with the progression of CKD stage; dif-
ferences in the risk owing to differences in underlying disease
of CKD were larger; and the risk was signiﬁcantly higher in
patients who had diabetic nephropathy than in patients who
did not.21 In the present study, the incidence of cardiovascular
events was signiﬁcantly higher in patients with DM despite
the fact that their blood glucose level was under relatively
good control. The presence of DM in CKD patients greatly
affects the prognosis. In the clinical management of CKD,
therefore, attention should be paid not only to the eGFR andand death among CKD-JAC, CRIC, and other epidemiologic
Rate (per 1000 person-years)
vascular
ease
Myocardial
infarction
Cerebrovascular
disease
Congestive heart
disease
All-cause
death
23 1.6 5.3 8.6 7.2
38 13 6 26 31
33 9 12 11 34
- 7.1/4.2 2.5/1.9 - -
- 5.0/1.4 - - -
- 0.6/0.1 - - -
- 1.6/0.7 5.3/3.9 - -
- 1.2/0.5 4.4/2.9 - -
dney Disease Japan Cohort; CRIC, Chronic Renal Insufﬁciency Cohort; F, female; JALS,
Determinants in Cardiovascular Disease.
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K Tanaka et al.: CVD risk in Japanese patients with CKD c l i n i ca l i nves t iga t ionCKD stage, but also to differences in the underlying disease
causing CKD.
The present study had several limitations. First, the sample
size was small. The numbers of cardiovascular events and all-
cause deaths (especially cardiovascular deaths) were much
lower than expected. Therefore, a larger sample size is required
to analyze the variables sufﬁciently that may be associated with
the primary end points. Second, ESRD could be a competing
risk factor for cardiovascular events or death because follow-up
evaluation was terminated in patients who started maintenance
dialysis therapy in the present study. Third, all of the patients in
the present study were outpatients who were under nephrology
care at major regional medical institutions. Therefore, patients
with greater awareness of their treatment probably were
selected. The number of nephrologists is insufﬁcient in Japan,
and a considerable numbers of patients withCKDdo not always
undergo appropriate treatment, are not managed at medical
institutions, or do not realize that they have CKD because of the
lack of prior medical examination. Hence, the results from the
present study might not be applicable to such patients. These
challenges need to be addressed by comparing the longer-term
observations in this cohort study with other ones.
The CKD-JAC Study is the ﬁrst to have shown the
incidences of cardiovascular events and all-cause death in
Japanese patients with predialysis CKD who were under
nephrology care. Japanese patients with predialysis CKD, who
were under nephrology care with strict management of blood
pressure, metabolism, and blood glucose, were at much lower
risk of developing cardiovascular events or death than CKD
patients in Western countries, although racial differences may
affect the risk. Whether or not the strict nephrology care of
CKD patients improves clinical outcomes requires further
research in a larger cohort study or an appropriately designed,
prospective, randomized, controlled trial.
MATERIALS AND METHODS
CKD-JAC
The CKD-JAC Study was designed as a prospective cohort study
involving approximately 3000 Japanese patients who were enrolled at
17 selected medical institutions in Japan, which play a central role in
the treatment of CKD patients in each area, to reﬂect practice patterns
in most of Japan. The protocol of the present study was published
previously.11,13 The inclusion criteria were as follows: (i) Japanese
patients living in Japan; (ii) age 20 to 75 years; and (iii) a broad
spectrumof CKD, deﬁned as an eGFRof 10 to 59ml/min/1.73m2. The
eGFR was calculated using the estimation equation for Japanese pa-
tients with CKD. This equation calculates the eGFR from serum
creatinine, age, and sex using the following formula: (eGFR [ml/min/
1.73 m2] ¼ 194  age-0.287  serum creatinine-1.094  [0.739 for
women]).22 The exclusion criteria were as follows: (i) patients with
polycystic kidney disease, human immunodeﬁciency virus infection,
cirrhosis, active cancer, or cancer treatment within the past 2 years; (ii)
transplant recipients and patients who previously have undergone
chronic dialysis; (iii) pregnant women; and (iv) individuals who refuse
to provide informed consent. Recruitment was started in September
2007, and 3087 patients were recruited. Twenty-seven patients were
excluded because they fulﬁlled any of the exclusion criteria, and
baseline data abstractionwas not completed for 25 patients. Sixty-nineKidney International (2017) 91, 227–234patients did not complete the baseline visit after enrollment: 59
withdrew their consent, 5 were excluded by the attending physician, 4
were lost to follow-up evaluation because they did not return to the
hospital, and 1 patient died. After eliminating these patients from the
registry, 2966 participants were followed up until March 2013. The
protocol was approved by the ethics committee of each participating
medical institution, and the study was conducted in accordance with
the Declaration of Helsinki. All patients provided written informed
consent.
Outcomes
Participants visited the clinical center every 6 months for in-person
follow-up visits, at which time they were asked about CVD-related
hospitalization and interventions. The follow-up evaluation of
patients who transferred to other medical institutions or started
maintenance dialysis therapy was terminated. The primary end
points were cardiovascular events and all-cause death before the
initiation of maintenance dialysis therapy. Cardiovascular events
(fatal and nonfatal myocardial infarction, angina pectoris, sudden
death, congestive heart failure, arrhythmias, cerebrovascular disor-
der, chronic arteriosclerosis obliterans, and aortic dissection) were
examined. All cardiovascular events were evaluated by the Inde-
pendent Cardiac Function Evaluation Committee. The detailed
deﬁnitions of cardiovascular events are described in Supplementary
Appendix S1.
Statistical analyses
The analytical plan for theCKD-JACStudywas published previously.11
Continuous variables of patient characteristics at baseline, expressed as
means  SD, were compared between groups by 1-way analysis of
variance. Incidences of cardiovascular events and all-cause death are
presented as the number of events per 1000 person-years. The in-
cidences of cardiovascular events also are shown separately by
myocardial infarction, cerebrovascular disease, congestive heart fail-
ure, others, and cardiovascular death (others includes angina pectoris,
sudden death, arrhythmias, chronic arteriosclerosis obliterans, and
aortic dissection). To test differences in event rates between DM and
non-DM, the Poisson model was used (Table 1). The Kaplan–Meier
curves and log-rank test were used to compare the event-free survival
of Japanese patients with predialysis CKD by CKD stage, who did or
did not have DM, based on competing-risk analysis that treated
noncardiovascular death as a competing event.23 A univariate analysis
by eGFR stage was conducted, andmultivariate survival analyses using
3 Cox proportional hazards models adjusted for confounding factors
were performed to examine associations between CKD stage at base-
line and the primary end points. In the presence or absence of DM,
model 1was used to calculate the hazard ratios adjusted for age and sex,
model 2 adjusted for BMI, DM, current smoking, spontaneous bac-
terial peritonitis, and history of CVD in addition to model 1, and
model 3 adjusted for hemoglobin, serum albumin, urine albumin, and
high-sensitivity C-reactive protein in addition to model 2. The results
from the models are expressed as hazard ratios with 95% conﬁdence
intervals) and P values based on the Wald chi-square statistic. A
2-tailed P value < 0.05 was considered signiﬁcant. All statistical ana-
lyses were performed using SAS software (version 9.4; SAS Institute,
Inc., Tokyo, Japan).
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Figure S1. Kaplan–Meier curves for the incidence of the primary end
points (cardiovascular events plus all-cause death) by chronic kidney
disease (CKD) stage at baseline unadjusted for confounding factors in
Japanese patients with predialysis CKD (without consideration of
competing events). Log-rank P < 0.001. CKD, chronic kidney disease.
Figure S2. Kaplan–Meier curves for the incidence of the primary end
points (cardiovascular events plus all-cause death) by chronic kidney
disease (CKD) stage at baseline in Japanese patients with predialysis
CKD and diabetes mellitus (DM) (without consideration of competing
events). Log-rank P ¼ 0.002.
Figure S3. Kaplan–Meier curves for the incidence of the primary end
points (cardiovascular events plus all-cause death) by chronic kidney
disease (CKD) stage at baseline in Japanese patients with predialysis
CKD who did not have diabetes mellitus (DM) (without consideration
of competing events). Log-rank P ¼ 0.038.
Table S1. Comparison of the incidences of cardiovascular events
among 17 medical institutions.
Appendix S1. A list of cardiovascular events that were treated and
their deﬁnitions.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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